Takeda Pharmaceutical Co (4502.T: Quote, Profile, Research, Stock Buzz), Japan’s biggest drugmaker, said on Friday that U.S. health authorities have not been able to complete a review of a key diabetes drug candidate on schedule due to lack of resources.
The drug, called alogliptin or SYR-322, is critical to Takeda’s mainstay diabetes business as it is expected to be the main replacement for its best-selling Actos.
A new study published in Wednesday’s Journal of the American Medical Association showed that the hormone-like chemical bisphenol A, or BPA, used in food containers and other household products may cause heart disease and diabetes at real-life levels.
The study found people with the highest level of the chemical ran nearly three times higher risk of cardiovascular disease than people with the lowest concentration. Their risk of Type 2 diabetes — the most common type — was 2.4 times as great.
To celebrate the beginning of National Hispanic Heritage Month and to recognize those in the
Hispanic/Latino population who have, or are at risk for, diabetes, the
American Diabetes Association is hosting Feria de Salud, Por Tu Familia on
Saturday, September 13 at St. Mary’s Park in the South Bronx from 11:00
a.m. - 4:00 p.m. Actor Tony Plana, who currently stars as Ignacio Suarez,
the widowed father in the ABC series “Ugly Betty” will be on hand to
support ADA’s outreach
Ensuring that patients’ blood sugar levels were closely regulated also led to them being 15 per cent less likely to have a heart attack.
More than two million people in Britain currently suffer from Type 2 diabetes, the most common kind, and experts estimate that that number could increase to four million by 2025, because of lifestyle issues such as obesity.
Diabetes occurs when the body loses the ability to control its blood sugar levels.
In a single generation’s time, type 2 diabetes has become so prevalent in children it’s no longer known by its traditional label of “adult-onset” diabetes.
Advertisement
With the link between diabetes and obesity firmly established, worries about weight gain and finding time to exercise that used to solely nag at adults are now a concern for kids and their parents.
Eli Lilly (LLY.N: Quote, Profile, Research, Stock Buzz) and Daiichi Sankyo’s (4568.T: Quote, Profile, Research, Stock Buzz) new blood-thinning drug prasugrel appears better for diabetes patients than Plavix, researchers said on Sunday.
Prasugrel — a rival to Plavix from Sanofi-Aventis (SASY.PA: Quote, Profile, Research, Stock Buzz) and Bristol-Myers Squibb (BMY.N: Quote, Profile, Research, Stock Buzz) — is a key product for Lilly and Daiichi. But its path to market has been delayed and the drug has been associated with serious bleeding.
Wednesday August 27, 2008 (foodconsumer.org) — Forget about stem cells research! Researchers at Harvard Medical School and Children’s Hospital in Boston have found a way for them to bypass stem cells to make special cells directly from adult cells, according to a study report released in the journal Nature.
Specifically, the researchers were able to turn adult cells into insulin producing beta cells, which is what type 1 diabetes patients need to produce insulin and metabolize blood sugar.
Some 3.4 million Medicare beneficiaries hit the so-called doughnut hole in drug coverage last year — and a sizable minority quit taking their medicine rather than pay full price out of pocket, a new report says.
At last year’s rate, Medicare beneficiaries were on the hook for prescription drugs after they incurred costs of $2,400. After a beneficiary spent $3,850 out-of-pocket, coverage kicked in again. That coverage gap is commonly referred to as the doughnut hole. (It doesn’t apply to low-income seniors, who qualify for a subsidy.)
ENGLEWOOD — For a few minutes during practice this week, Wade Wilson and Jay Cutler chatted not about footwork or arm slots or hot reads, but about real life.
Wilson, the Cowboys quarterbacks coach, and Cutler, Denver’s starting quarterback, spoke about blood sugar and insulin pumps and managing life with Type 1 diabetes.
Mark Butts Jr. cries when he thinks about how close he came to losing his son.
Mark Butts III (left), 12, and his brother Christopher, 10, shoot hoops near their home. Mark is the youngest in his family to have Type2 diabetes. The family now makes an effort to exercise at least 30 minutes a day.
The Coppell father of four was rounding up the family Sept. 2 for a trip to Six Flags Over Texas. But a glassy look on the face of his eldest, 12-year-old Mark Butts III, brought back a terrifying memory.
